Remuun provides a proprietary MEGA platform that automates high‑throughput antibody discovery and engineering, enabling the generation of therapeutic monoclonal antibodies up to 50 times faster than traditional methods. By integrating robotic workflows, computational modeling, and real‑time analytics, the platform shortens development cycles, lowers R&D costs, and helps pharma, biotech, and academic partners accelerate preclinical and clinical programs.
Funding
Funding not disclosed
Founders
Product
Problem
Developing therapeutic monoclonal antibodies traditionally requires lengthy, resource‑intensive processes, delaying the delivery of new treatments to patients and increasing development costs.
Solution
Remuun addresses this bottleneck with its proprietary MEGA platform, a high‑throughput antibody discovery and engineering system designed to generate therapeutic candidates up to 50 times faster than conventional methods. The platform integrates advanced molecular biology, automation, and data‑driven selection to streamline the entire antibody pipeline—from antigen screening to lead optimization. By reducing cycle times and improving hit rates, Remuun enables partners to accelerate preclinical and clinical programs, lower R&D expenditures, and bring effective biologics to market more quickly.
Target Audience
Primary customers are pharmaceutical companies, biotech firms, and academic research groups seeking accelerated development of monoclonal antibody therapeutics.
Features
- Automated high‑throughput screening of large antibody libraries using robotic workflows
- Integrated computational modeling for rapid affinity maturation and specificity assessment
- Scalable expression and purification pipelines that produce clinical‑grade antibodies in weeks
- Real‑time analytics dashboard for tracking candidate progression and decision points
- Modular workflow that can be customized for diverse therapeutic targets and disease areas